ALIMTA
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
ALIMTA by Eli Lilly and Company is folate-dependent metabolic processes essential for cell replication. Approved for non-small cell lung cancer, non-small cell lung cancer [see clinical studies ()]. First approved in 2004.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALIMTA (pemetrexed) is a small-molecule antimetabolite that inhibits folate-dependent enzymes critical for DNA synthesis, used to treat non-small cell lung cancer. It works by blocking thymidylate synthase, dihydrofolate reductase, and GARFT, disrupting nucleotide biosynthesis in rapidly dividing cancer cells. Patients receive the drug via intravenous injection.
$0.002BPart D
LOE ApproachingProduct approaching end-of-life with modest Part D utilization; brand teams should anticipate resource reallocation and transition planning within 2-3 years.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis…
Indications (1)
Clinical Trials (21)
TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
Started Jul 2011
148 enrolled
Carcinoma, Non Small Cell Lung
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Started Nov 2009
236 enrolled
Non Small Cell Lung Cancer
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
Started Jan 2009
18 enrolled
Central Nervous System Lymphoma
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Started Jan 2009
6 enrolled
MesotheliomaPleural Mesothelioma
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Started Apr 2008
228 enrolled
Non Small Cell Lung Carcinoma
Worked on ALIMTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.